TCL Archive Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study December 26, 2014
TCL Archive In Brief: Yarbro To Leave As NCI Centers Chief to Head Missouri Cancer Program; Replaced By Cantril May 30, 1975